ProACT Post-Approval Study

Description

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Conditions

Stress Urinary Incontinence

Talk to us

Study Overview

On this page

Study Details

Study overview

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men

ProACT Post-Approval Study

Condition
Stress Urinary Incontinence
Intervention / Treatment

-

Contacts and Locations

Denver

University of Colorado, Denver, Colorado, United States, 80045

Gainesville

University of Florida, Gainesville, Florida, United States, 32610

Atlanta

Emory University, Atlanta, Georgia, United States, 30322

Kansas City

University of Kansas Medical Center, Kansas City, Kansas, United States, 66103

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Saint Cloud

CentraCare- St. Cloud, Saint Cloud, Minnesota, United States, 56303

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Subject is a male of at least 50 years of age.
  • 2. Subject demonstrates stress urinary incontinence.
  • 3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
  • 4. Subject is willing and able to undergo surgical implantation of ProACT devices.
  • 5. Subject is willing and able to comply with study-required
  • 6. Subject is willing and able to sign the approved informed consent.
  • 7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
  • 8. Subject has a negative urine culture.
  • 9. Subject has no known urogenital malignancy, other than previously treated prostate cancer.
  • 10. Subject meets ONE of the following criteria:
  • 1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
  • 2. Baseline PSA \> 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
  • 11. Physician determines subject to be a suitable surgical candidate.
  • 1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
  • 2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
  • 3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
  • 4. Subject has undergone radiation therapy in the prostatic area within the last 12 months.
  • 5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
  • 6. Subject has an atonic bladder.
  • 7. Subject had, presently has, or is suspected of having bladder cancer.
  • 8. Subject has untreated or unsuccessfully treated bladder stones.
  • 9. Subject has detrusor sphincter dyssynergia.
  • 10. Subject has known hemophilia or a bleeding disorder.
  • 11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
  • 12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Uromedica,

Timothy C Cook, PhD, STUDY_DIRECTOR, Uromedica, Inc.

Study Record Dates

2030-09-01